^
    Back
    Association details:
    Biomarker:EPHA5 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:Tecentriq (atezolizumab) (PD-L1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    BMC Pulm Med
    Title:

    EPHA5 mutation was associated with adverse outcome of atezolizumab treatment in late-stage non-small cell lung cancers

    Published date:
    09/19/2022
    Excerpt:
    Patients with EPHA5 mutation got worse survival compared to those without gene mutations receiving atezolizumab (P = 0.0186).
    DOI:
    https://doi.org/10.1186/s12890-022-02161-1
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Lung Cancer
    Title:

    PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab

    Published date:
    11/13/2020
    Excerpt:
    Worse survival could be found in patients with KEAP1 (P < 0.001), TP53 (P = 0.004) and EPHA5 (P = 0.013) mutations who received atezolizumab compared with those who had none of these gene mutations.
    DOI:
    10.1016/j.lungcan.2020.11.006